Agoracom: Small Cap Investment - Mannkind - Afrezza sales could be higher than Exubera, says Summer Street

Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Reply New Message

Back To Forum List View

brentie98

Rank: President [?]

Points: 5496 [?]

Votes: 21 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Afrezza sales could be higher than Exubera, says Summer Street

posted on Jul 16, 2013 09:52AM

"Summer Street believes that if approved, sales of MannKind's (MNKD) inhalable insulin Afrezza could be "substantially higher" than Pfizer’s (PFE) Exubera given Afrezza’s ease of use. However, the firm adds that it cannot accurately predict future sales of Afrezza at this time."

http://www.theflyonthewall.com/permalinks/entry.php/MNKD;PFEid1858409/MNKD;PFE-Afrezza-sales-could-be-higher-than-Exubera-says-Summer-Street